Compare
OSR Health, Inc. vs QHSLab, Inc. vs Nuo Therapeutics, Inc. vs IceCure Medical Ltd.
| Latest fiscal year | OSR Health, Inc. OSRH | QHSLab, Inc. USAQ | Nuo Therapeutics, Inc. AURX | IceCure Medical Ltd. ICCM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.91M | $2.69M | $3.31M | $3.38M |
| Revenue growth (YoY) | -17.7% | +26.3% | +142.7% | +2.7% |
| Gross margin | 20.4% | 67.3% | 66.9% | 36.3% |
| Operating margin | -631.0% | 4.9% | -76.0% | -446.7% |
| Net margin | -931.2% | 17.0% | -75.8% | -445.6% |
| Net income | -$27.06M | $457.4K | -$2.51M | -$15.06M |
| EPS (Diluted) | -$0.80 | $0.02 | n/a | $0.24 |
| Operating cash flow | -$4.33M | $178.1K | -$865.0K | -$14.57M |
| Free cash flow | n/a | n/a | -$1.14M | -$14.61M |
| Cash & equivalents | $1.70M | $636.2K | $548.9K | $8.90M |
| Total assets | $171.24M | $2.17M | $1.85M | $13.89M |
| Total liabilities | $44.20M | $546.1K | $2.80M | n/a |
| Shareholders' equity | $127.04M | $1.62M | -$956.6K | $9.05M |
| Return on year-end equity | -21.3% | 28.1% | n/a | -166.4% |
| Shares outstanding | 26.60M | 15.03M | 48.18M | 73.12M |
Revenue, most recent five fiscal years
| Fiscal year | OSR Health, Inc. | QHSLab, Inc. | Nuo Therapeutics, Inc. | IceCure Medical Ltd. |
|---|---|---|---|---|
| Latest | $2.91M Ended 2025-12-31 | $2.69M Ended 2025-12-31 | $3.31M Ended 2025-12-31 | $3.38M Ended 2025-12-31 |
| 1 year earlier | $3.53M Ended 2024-12-31 | $2.13M Ended 2024-12-31 | $1.37M Ended 2024-12-31 | $3.29M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.41M Ended 2023-12-31 | $608.5K Ended 2023-12-31 | $3.23M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.24M Ended 2022-12-31 | $112.2K Ended 2022-12-31 | $3.08M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.41M Ended 2021-12-31 | $0 Ended 2021-12-31 | $4.14M Ended 2021-12-31 |